Trials / Completed
CompletedNCT00235794
An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients
An Open Label Study of Exploratory Pharmacogenomics and Pharmacologic Effects of Neoadjuvant Oral Temsirolimus in Newly Diagnosed Prostate Cancer Patients Undergoing Radical Prostatectomy Who Have a High Risk of Relapse
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open-label exloratory pharmacodynamic and pharmacogenomic study to evaluate teh biologic effects of 3 dose levels (1mg, 5 mg, and 15 mg) of temsirolimus administered orally once daily for approximately 4 weeks (+/- 2 weeks) before prostatectomy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | temsirolimus |
Timeline
- Start date
- 2004-01-01
- Completion
- 2007-09-01
- First posted
- 2005-10-10
- Last updated
- 2007-12-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00235794. Inclusion in this directory is not an endorsement.